



261 Mountain View Dr  
 Colchester, VT 05446  
 License #: TLAB0030  
 802-767-7256  
 info@onwardanalytics.biz

# Certificate of Analysis

**Client Name:** Vermont Kind  
**License Number:** SCLT0186

**Sample ID:** VT13989  
**Sample Name:** Grimm Glue Virgin Extract  
**Sample Lot:** MANU0027-TP0009  
**Sample Matrix:** Solvent Extraction Concentrates  
**Date Received:** 10/9/2024  
**Date Reported:** 10/16/2024  
**Date Tested:** 10/11/2024



**Total Terpenes (%) : 5.3379**

### Dominant Terpenes (%)

beta-caryophyllene	2.262
alpha-Humulene	1.1388
Limonene	0.714
alpha-Bisabolol	0.4354
Nerolidol	0.185

## Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #43053

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.4354	4.354	0.000003	0.001
alpha-Humulene	1.1388	11.388	0.000002	0.001
alpha-Pinene	0.0536	0.536	0.000001	0.001
alpha-Terpinene	< LOQ	< LOQ	0.000001	0.001
alpha-Terpinolene	< LOQ	< LOQ	0.000004	0.001
beta-caryophyllene	2.262	22.62	0.000004	0.001
beta-Pinene	0.0844	0.844	0.000002	0.001
Camphene	0.0115	0.115	0.000001	0.001
Caryophyllene Oxide	0.1345	1.345	0.000011	0.001
Eucalyptol	0.0211	0.211	0.000002	0.001
gamma-Terpinene	< LOQ	< LOQ	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	0.013	0.13	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.714	7.14	0.000002	0.001
Linalool	0.1137	1.137	0.000003	0.001
Nerolidol	0.185	1.85	0.000007	0.001
Myrcene	0.1709	1.709	0.000003	0.001
Ocimene	ND	ND	0.000002	0.001
<b>Total Terpenes</b>	<b>5.3379</b>	<b>53.379</b>		



*Callie Chapman*

Callie Chapman  
 Lab Director  
 10/16/2024

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

